Abstract 98P
Background
Lung cancer represents the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for ∼85% of total cases. Although immunotherapy using immune checkpoint inhibitors (ICI) has shown promising results, only a subset of patients benefits from it and there is an urgent need for reliable predictive response biomarkers. Furthermore, traditional tissue biopsies are limited in size and provide a biased representation of the tumour. Therefore, we aimed to explore the possibility to obtain predictive biomarkers of response to ICI in a non-invasive way using liquid biopsy (LB).
Methods
To counter this, we analysed samples from 25 patients from advanced NSCLC treated with pembrolizumab at first line. Blood and tissue samples were collected at baseline to obtain cell-free DNA (cfDNA) and genomic DNA from plasma and PBMCs respectively, and tumour DNA from FFPE primary tumour. All samples underwent a target NGS panel to call somatic mutations in circulating tumour DNA (ctDNA) and primary tumour, evaluating their potential as predictive biomarkers.
Results
Through the integration of three different bioinformatic approaches for variant calling and ROC curve analysis, we identified mutations in key cancer-related genes associated with a 3-month radiological response. We also assessed a promising mutational signature in ctDNA comprising 10 genes with a high ability to predict response to ICI (AUC = 0.98). Although we explored copy number alterations and tumour mutational burden in LB, results did not yield statistical significance, suggesting that assessment of point mutations in particular genes and the proposed signature hold higher potential as biomarkers. Moreover, we compared ctDNA analysis with tissue biopsies, revealing a high concordance between ctDNA and primary tumour, enhancing the reliability of ctDNA analysis as a good alternative for tumour assessment.
Conclusions
These findings highlight the value of ctDNA analysis as a non-invasive predictive biomarker for ICI response and its correlation with mutations found in primary tumours. We also proposed a mutational signature to predict response at baseline for advanced NSCLC ICI treated patients, which could be readily implemented in the clinical management of the disease.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Translational Molecular Oncology Unit. IIS Galicia Sur.
Funding
Vigo Contra el Cáncer; GAIN; Xunta de Galicia (ED481A-2020/214); Miguel Servet program (CP20/00188).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract